Pepgen reports second quarter 2022 financial results and recent corporate developments

Boston, aug. 12, 2022 (globe newswire) -- pepgen inc. (“pepgen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended june 30, 2022.
PEPG Ratings Summary
PEPG Quant Ranking